The Plasminogen Ability In Patients With Polycystic Ovary Syndrome And It's Clinical Significance

Part ⅠThe ability of PAI-1 and t-PA in patients with polycystic ovary syndrome Objective: To evaluate the plasminogen activator system in patients with polycystic ovary syndrome (PCOS). Methods: Serum free-testosterone(F-T), insulin(INS), tissue plasminogen activator(t-PA), plasminogen activator inhibitor type-1(PAI-1) activity of thirty-five women with PCOS and twenty controls were measured. Results: The serum insulin is higher (mean ±SD: 19.28 ±10.50mU/L),t-PA is lower(0.21±0.04KU/L) and PAI-1 is higher(0.86±0.05AU/ml) in patients with PCOS than controls. Conclusions: The plasminogen ability is lower in patients with PCOS。Part ⅡThe plasminogen ability in Patients with polycystic ovary syndrome before and after metformin administration Objective: To determine whether metformin would increase the plasminogen ability in PCOS patients. Methods: Serum free-testosterone(F-T), insulin(INS), tissue plasminogen activator(t-PA), plasminogen activator inhibitor type-1(PAI-1) activity were measured before and after a month oral administration of metformin 750 mg ~ 1500 mg daily in fifteen women with PCOS who had hyperinsulinism,. Results: The serum insulin is higher (mean±SD:23.41±8.11mU/L), t-PA is lower(0.17±0.06KU/L) and PAI-1 is higher(0.88±0.05AU/ml) in fifteen women with PCOS than controls. Serum INS, t-PA, PAI-1 were 15.64±5.34mU/L, 0.26±0.08KU/L, 0.82±0.96AU/ml respectively after one month metformin administration. Conclusions: Metformin can increase the plasminogen ability in women with polycystic ovary syndrome.